Quantum Blue®

The Quantum Blue^® rapid test combines the ease and speed of lateral flow technology (using a highly specific monoclonal antibody to calprotectin), with full quantification by means of a small, telephone sized reading device. The Quantum Blue^® Reader analyzes the signal intensity from the test and control line to give a quantitative value and is standardized with the BÜHLMANN fCAL^® ELISA.

Quantum Blue^® fCAL high range: Health Canada License: 88674
Quantum Blue^® fCAL extended: Health Canada License: 100161
Quantum Blue^®Infliximab: Health Canada Licence: 98838
Quantum Blue^®Adaliumumab: Health Canada Licence: 101776

US: (The Quantum Blue^® tests are for Research Use Only. Not for use in diagnostic procedures in the US.)

Quantum Blue^® – fCAL 

The Quantum Blue^® fCAL lateral flow assay combines the ease and speed of lateral flow technology (using a highly specific monoclonal antibody to calprotectin), with full quantification by means of a small, telephone sized reading device and the result is obtained within 12-15 minutes.  The Quantum Blue^® Reader analyzes the signal intensity from the test and control line to give a quantitative value and is standardized with the BÜHLMANN fCAL^® ELISA.

Quantum Blue^® – Infliximab

The BÜHLMANN Quantum Blue^® Infliximab is the first rapid test to measure infliximab in serum samples. The test is designed for the selective measurement of infliximab by a sandwich immunoassay  and provides a quantitative result within 15 minutes. Quantum Blue^® Infliximab is unique, being the ONLY test that can provide fast, reliable information for infliximab, and correlating well with the standard routine ELISAs for determination of infliximab levels.

Quantum Blue^® – Adalimumab

The BÜHLMANN Quantum Blue^® Adalimumab is the ONLY rapid test to measure adalimumab in serum samples. The test is designed for the selective measurement of adalimumab by a sandwich immunoassay. Quantum Blue^® Adalimumab is unique in the market, being the ONLY test that can provide fast, reliable information for adalimumab and it correlates well with the standard routine ELISAs for adalimumab level determinations.

Quantum Blue^® – hsCRP

The Quantum Blue^® hsCRP lateral flow assay is designed for the quantitative determination of CRP in human serum in combination with the BÜHLMANN Quantum Blue^® Reader. Less than 50 µl serum is required to perform the lateral flow test for CRP. The intended use of Quantum Blue ^® hsCRP is for the study of irritable bowel disease (IBD) related research.

Download IFU and Catalog Numbers^‡

View the appropriate tab below for your location (US or Canada) and click on the blue underlined catalog number to view the Instructions for Use.